Chana Peysin

Poly(ADP-Ribose) Polymerase Inhibition in Melanoma: Biological Rationale, Emerging Clinical Evidence, and Biomarker Selection

Immune checkpoint inhibitors and other targeted therapies have substantially improved outcomes for patients with advanced melanoma; however, effective treatment options remain limited following treatment resistance. Poly(ADP-ribose) polymerase (PARP) inhibitors are an established...